Carla Verri

Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study.

Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.

Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: a validation analysis.

Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk.

MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.

Assessment of circulating microRNAs in plasma of lung cancer patients.

YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.

Therapeutic use of microRNAs in lung cancer.

Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging.

Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.

Novel method to detect microRNAs using chip-based QuantStudio 3D digital PCR.

MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature.

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers.